Achillion Strengthens Clinical Team, Readies HCV Nuc For Clinical Development
This article was originally published in The Pink Sheet Daily
Executive Summary
CSO Milind Deshpande will succeed Michael Kishbauch as CEO, while two HCV veterans from other companies will strengthen Achillion’s clinical development team. Meanwhile, the virology firm expects to file an IND for a nucleoside polymerase inhibitor later this year; only two antivirals from that class currently are in clinical development in HCV.